PolymarketVerificar disponibilidadeSem KYCDados de resolução verificadosBem calibradoAviso de qualidade dos dadosSem cotações ao vivo
Dados de 5 de out. de 2026, 22:11 UTC · política pm-quality-4
Probabilidade implícita atual
June 30, 83%
June 30, 83%Qualidade do mercado
≤49 / 100
Baixa qualidadeVolume 24h
—
Liquidez
7 mil €
Liquidez médiaCompra / Venda
82.0% / 83.0%
Spread
1.0 pt
Spread apertadoComentários
0
Dados do mercado
Atualizado há 5 minutos
19/08/26, 18:47 UTC1/07/27, 03:59 UTC
Tendências
Condições da plataforma
Fonte: Polymarket
Estas condições são informativas; as operações simuladas da CoinRithm seguem regras próprias.
- Ordem mínima (cotas):
- 5
- Incremento de preço:
- 1 pontos percentuais
- Taxas:
- Sim
Mercados Relacionados
Perguntas relacionadas para dar contexto, não uma comparação de contratos equivalentes.
FDA approves skin cancer vaccine by which date?
PolymarketIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsWill the Russian cancer vaccine work?
Manifold MarketsIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsWhat will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold MarketsWill CDC cut the childhood vaccine schedule below 11 diseases in 2026?
KalshiRegras
This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET.
- Otherwise, this market will resolve to "No".
- Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
- A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA).
- An original BLA or a resubmission of such a BLA following FDA action will qualify.
- The application may cover any indication.